Related Experiment Video
Updated: Apr 17, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
[Efavirenz and risk of suicide in HIV patients]
David M Burger1, Quirijn de Mast, Arnt F A Schellekens
1Radboudumc, Nijmegen.
Abstract:
Efavirenz is widely used as part of combination antiretroviral therapy in HIV-infected patients. Central nervous system adverse effects are the most important reason for discontinuation of this drug. A recent combined analysis of phase III data showed a two-fold increased risk of suicidal ideation or suicide attempts, when compared with non-efavirenz-containing regimens. This commentary discusses the data from this analysis, tries to explain these observations and the implications for clinical practice, and puts them into perspective in relation to efavirenz's prominent position as a first-line drug for the treatment of HIV infection.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
05:53Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
Related Concept Videos
Retrovirus Life Cycles
Drug Toxicity: Risk factors
Inhibitors of Viral Protein Synthesis
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Antidepressant Drugs: Overview
Antidepressant Drugs: MAOIs and Other Agents